Advaxis (OTCMKTS:ADXS – Get Rating) and NRx Pharmaceuticals (NASDAQ:NRXP – Get Rating) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, profitability, earnings, dividends, analyst recommendations, valuation and institutional ownership.

Institutional and Insider Ownership

6.7% of Advaxis shares are owned by institutional investors. Comparatively, 3.9% of NRx Pharmaceuticals shares are owned by institutional investors. 0.3% of Advaxis shares are owned by company insiders. Comparatively, 27.1% of NRx Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Advaxis and NRx Pharmaceuticals' net margins, return on equity and return on assets.

Volatility and Risk

Analyst Recommendations

This is a summary of recent recommendations for Advaxis and NRx Pharmaceuticals, as reported by MarketBeat.com.

NRx Pharmaceuticals has a consensus price target of $2.00, indicating a potential upside of 196.21%. Given NRx Pharmaceuticals' higher possible upside, analysts plainly believe NRx Pharmaceuticals is more favorable than Advaxis.

Earnings & Valuation

This table compares Advaxis and NRx Pharmaceuticals' revenue, earnings per share and valuation.

Advaxis has higher revenue and earnings than NRx Pharmaceuticals. Advaxis is trading at a lower price-to-earnings ratio than NRx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Advaxis beats NRx Pharmaceuticals on 7 of the 11 factors compared between the two stocks.

About Advaxis

(Get Rating)

Advaxis, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of proprietary Listeria monocytogenes (Lm) technology antigen delivery products in the United States. The company is developing ADXS-PSA, which is in Phase 2 clinical trials for the treatment of metastatic prostate cancer; ADXS-503 that is in Phase 1/2 clinical trials for the treatment of non-small cell lung cancer; and ADXS-504 for the treatment of prostate cancer. It is also conducting clinical studies of Lm Technology immunotherapies in the following areas of disease focused hotspot/off-the-shelf neoantigen-directed therapies; human papilloma virus-associated cancers; and prostate cancer. The company has collaborations and partnerships with Merck & Co., Inc.; OS Therapies, LLC; Aratana Therapeutics Inc.; Biocon Limited; Global BioPharma Inc.; Knight Therapeutics Inc; and others. Advaxis, Inc. was founded in 2002 and is based in Monmouth Junction, New Jersey.

About NRx Pharmaceuticals

(Get Rating)

NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware.

Receive News & Ratings for Advaxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis and related companies with MarketBeat.com's FREE daily email newsletter.